Current review examines oral anti-diabetic drugs and their structure-activity relationships, suggesting improvement in diabetes treatment outcomes.
Diabetes mellitus, a chronic metabolic disorder, poses a significant global health challenge, demanding continuous research into effective treatments. With projections of 629 million individuals affected by 2045 and escalating healthcare costs, the need for new anti-diabetic medications is urgent. Current therapies often present limitations, including undesirable side effects and insufficient long-term efficacy. This review explores the development of oral anti-diabetic drugs (OADs), focusing on the structure-activity relationship (SAR) employed to create both established and emerging classes of medications. We examine the six major OAD classes: biguanides, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, and SGLT2 inhibitors. In addition, a new promising class of OAD, namely metal complexes, is discussed. This review highlights the crucial role of synthetic chemistry in advancing diabetes treatment and improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Mutalabisin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: